Challenges with benchmarking of MDMA-assisted psychotherapy
Nat Med
.
2021 Oct;27(10):1689-1690.
doi: 10.1038/s41591-021-01525-0.
Epub 2021 Oct 11.
Authors
Joar Øveraas Halvorsen
1
2
,
Florian Naudet
3
,
Ioana A Cristea
4
Affiliations
1
Department of Psychology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. joar.halvorsen@ntnu.no.
2
St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. joar.halvorsen@ntnu.no.
3
CHU Rennes, INSERM CIC 1414 (Centre d'Investigation Clinique de Rennes), University Rennes, Rennes, France.
4
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
PMID:
34635857
DOI:
10.1038/s41591-021-01525-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Benchmarking
Humans
N-Methyl-3,4-methylenedioxyamphetamine*
Psychotherapy
Stress Disorders, Post-Traumatic*
Substances
N-Methyl-3,4-methylenedioxyamphetamine